Company intelligence / Profile preview
Luzitin
Coimbra / São Martinho do Bispo, Centro Region / Coimbra District, Portugalluzitin.pt ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Redaporfin demonstrated safety, tolerability, and efficacy signals in a proof-of-concept trial for advanced head and neck cancer. The drug has orphan drug designation from the EMA for biliary tract cancer. A pivotal Phase III trial is being planned.[3][6] LUZACNE program targeting moderate to severe acne remains at an early stage.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Photosensitizing small molecules (photosensitizers) for photodynamic therapy (PDT) and photodiagnosis (PDD)[1][2][4][5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of CoimbraBluepharma S.A.InovCapital/Portugal Ventures S.A.[5]seeking licensing partners at BIO-Europe/BIO International events[3]academic collaborations with Coimbra University Hospitals
Beyond the preview
Go deeper on Luzitin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luzitin.